154 related articles for article (PubMed ID: 27127135)
1. The Involvement of PDGF-B/PDGFRβ Axis in the Resistance to Antiangiogenic and Antivascular Therapy in Renal Cancer.
Cumpănas AA; Cimpean AM; Ferician O; Ceausu RA; Sarb S; Barbos V; Dema A; Raica M
Anticancer Res; 2016 May; 36(5):2291-5. PubMed ID: 27127135
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-β (PDGF-β), and PDGF-β receptor expression in papillary renal cell carcinoma.
Kim M; Sohn M; Shim M; Choi SK; Park M; Kim E; Go H; Park Y; Cho YM; Ro JY; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
Hum Pathol; 2017 Mar; 61():78-89. PubMed ID: 27989785
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer.
Suzuki S; Dobashi Y; Hatakeyama Y; Tajiri R; Fujimura T; Heldin CH; Ooi A
BMC Cancer; 2010 Nov; 10():659. PubMed ID: 21118571
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro.
Pfister C; Pfrommer H; Tatagiba MS; Roser F
Br J Cancer; 2012 Nov; 107(10):1702-13. PubMed ID: 23047550
[TBL] [Abstract][Full Text] [Related]
6. Effect of platelet-derived growth factor-B on renal cell carcinoma growth and progression.
Wang W; Qi L; Tan M; Zhang Z; Du J; Wei X; Yao X
Urol Oncol; 2015 Apr; 33(4):168.e17-27. PubMed ID: 25766258
[TBL] [Abstract][Full Text] [Related]
7. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF.
Murphy EA; Shields DJ; Stoletov K; Dneprovskaia E; McElroy M; Greenberg JI; Lindquist J; Acevedo LM; Anand S; Majeti BK; Tsigelny I; Saldanha A; Walsh B; Hoffman RM; Bouvet M; Klemke RL; Vogt PK; Arnold L; Wrasidlo W; Cheresh DA
Proc Natl Acad Sci U S A; 2010 Mar; 107(9):4299-304. PubMed ID: 20154271
[TBL] [Abstract][Full Text] [Related]
8. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
9. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets.
Yin X; Lin X; Ren X; Yu B; Liu L; Ye Z; Chen Q; Lee C; Lu W; Yu D; Li X
Pharmacol Res; 2019 Aug; 146():104277. PubMed ID: 31112749
[TBL] [Abstract][Full Text] [Related]
10. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
[TBL] [Abstract][Full Text] [Related]
11. Current overview of angiogenesis inhibitors.
Ellis LM
Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
[No Abstract] [Full Text] [Related]
12. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Rini BI
Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
[TBL] [Abstract][Full Text] [Related]
13. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression.
Tsioumpekou M; Cunha SI; Ma H; Åhgren A; Cedervall J; Olsson AK; Heldin CH; Lennartsson J
Theranostics; 2020; 10(3):1122-1135. PubMed ID: 31938055
[TBL] [Abstract][Full Text] [Related]
14. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
Lu C; Thaker PH; Lin YG; Spannuth W; Landen CN; Merritt WM; Jennings NB; Langley RR; Gershenson DM; Yancopoulos GD; Ellis LM; Jaffe RB; Coleman RL; Sood AK
Am J Obstet Gynecol; 2008 Apr; 198(4):477.e1-9; discussion 477.e9-10. PubMed ID: 18395047
[TBL] [Abstract][Full Text] [Related]
15. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
16. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
17. bFGF and PDGF-BB have a synergistic effect on the proliferation, migration and VEGF release of endothelial progenitor cells.
Sufen G; Xianghong Y; Yongxia C; Qian P
Cell Biol Int; 2011 May; 35(5):545-51. PubMed ID: 20961291
[TBL] [Abstract][Full Text] [Related]
18. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.
Xu L; Tong R; Cochran DM; Jain RK
Cancer Res; 2005 Jul; 65(13):5711-9. PubMed ID: 15994946
[TBL] [Abstract][Full Text] [Related]
19. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
Saylor PJ; Escudier B; Michaelson MD
Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
[TBL] [Abstract][Full Text] [Related]
20. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling.
Kano MR; Morishita Y; Iwata C; Iwasaka S; Watabe T; Ouchi Y; Miyazono K; Miyazawa K
J Cell Sci; 2005 Aug; 118(Pt 16):3759-68. PubMed ID: 16105884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
